Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for ONCO. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: ONCO is a Sell candidate.
ONCO stock price ended at $1.65 on 星期四, after rising 3.12%
On the latest trading day Jan 22, 2026, the stock price of ONCO rose by 3.12%, climbing from $1.73 to $1.65. During the session, the stock saw a volatility of 16.56%, with prices oscillating between a daily low of $1.51 and a high of $1.76. Notably, trading volume dropped by 1.0M shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.0M shares were traded, equating to a market value of approximately $2.5M.